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ABSTRACT 
Introduction: Although patients with an acute increase in airflow resistance may require 
aerosol therapy and noninvasive positive pressure ventilation (NIPPV), the efficiency of 
different aerosol devices and masks during NIPPV is not well understood. The purpose of 
this study was to determine the efficiency of a jet nebulizer (JN), a vibrating mesh 
nebulizer (VMN) and a pressurized metered-dose inhaler (pMDI) and three different 
masks during NIPPV. 
Method: An in vitro lung model consisted of the upper airway of an adult teaching 
manikin with a collecting filter at the level of the bronchi attached to a passive test lung. 
NIPPV was administered via full face mask for the first experiment (AF531 oro-nasal) 
with an IPAP/EPAP of 20/5 cm H2O and a respiratory rate of 15 Breath per minute 
(BPM). Aerosol generators were placed between the leak in the circuit and the mask. 
Albuterol sulfate (2.5 mg/ 3 ml) was nebulized with the JN (Micromist) and the VMN 
(Aeroneb Solo). Four puffs (108 µg/puff) were administered with the pMDI (ProAir 
HFA) with a spacer (Aerovent) that first was placed in the recommended normal position 
(pMDI-N) with aerosol plume directed towards patient, and then in the reversed position 
(pMDI-R), with aerosol directed away from patient (n=3). In the second experiment, 
three masks were used 1) the Performax mask, 2) the AF531 oro-nasal mask, and 3) the 
Performa track mask.  Performa track mask was tested with only Aeroneb solo while 
other masks were tested with both Aeroneb solo and NIVO VMNs. In both experiments, 
filters were eluted with 0.1 HCl and analyzed by a spectrophotometer at 276 nm. 
Residual volumes were determined gravimetrically. 
Result: Descriptive statistics, one-way analysis of variance (ANOVA), and independent t 
tests were used. Statistical significance was set at p<0.05. During NIPPV, inhaled mass 
(IM) and inhaled mass percent (IM %) varied significantly (p=0.042 and p=0.028, 
respectively). Aerosol delivery with the JN was the lowest during NIPPV. The VMN has 
a significantly lower residual volume than the JN (p=0.0001). No statistical difference in 
efficiency was found between the two pMDI orientations (p=0.253). In the second 
experiment, oro nasal mask with Aeroneb Solo VMN results in the highest IM which was 
significant when compared with all other masks(p=0.0001). No statistical difference can 
be found between other masks.  
Conclusion: The JN was less efficient than the VMN and the pMDI in either orientation. 
The type of aerosol device used during NIPPV influenced aerosol delivery in this 
simulated adult lung model. Oro nasal mask with Aeroneb Solo VMN provided the 
highest IM. 
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CHAPTER I  
INTRODUCTION 
Noninvasive positive pressure ventilation (NIPPV) can be delivered to a patient 
with an intact airway through a face mask or similar interface (Crummy & Naughton, 
2007). By leaving the upper airway intact, NIPPV preserves airway defense mechanisms, 
and patients are able to eat and drink, speak, cough and expectorate secretions, and avoid 
specific complications associated with an endotracheal tube, such as ventilator-associated 
pneumonia, sinusitis, and tracheal stenosis (Crummy & Naughton, 2007). In addition, 
patients may not need to be on sedatives, analgesics, or paralytics to start or maintain 
NIPPV. In a 2003 meta-analysis involving eight studies with more than 600 patients, 
Lightowler and his colleagues showed that the use of NIPPV resulted in a highly 
significant reduction in mortality rate (relative risk 41%) and the need for intubation 
(relative risk 42%). They concluded that NIPPV is an effective intervention in the 
management of acute respiratory failure secondary to acute hypercapnic exacerbations of 
chronic obstructive pulmonary disease (COPD). 
NIPPV is a very cost-effective intervention, avoiding intubation and intensive 
care unit (ICU) admission, without prolonging hospital length of stay (Plant, Owen, 
Parrott, & Elliott, 2003). It also can be used safely on the general ward (Al-Mutairi & Al-
Deen, 2004; Crummy & Naughton, 2007), which could avoid the need for ICU 
admission. Plant, Owen, Parrott, and Elliott (2003) have suggested that treatment with 
NIPPV may avoid between three and nine ICU admissions per year in a regional UK 
general hospital, resulting in a potential annual cost saving of up to £53 000 
(US$125,000). 
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During NIPPV, alveolar ventilation is improved by the application of positive 
pressure through a nasal mask, oral mask, face mask, full face mask, or hamlet, thereby 
avoiding the need for an endotracheal or tracheostomy tube to perform invasive 
ventilation. Inhaled aerosol therapy has gained widespread acceptance because of its 
advantages over other alternative routes for drug administration (Ari, Hess, Myers, & 
Rau, 2009). 
A ―medical aerosol‖ is any suspension of liquid (nebulizer or pressurized 
metered-dose inhaler [pMDI]) or solid drug particles (pMDI or dry powder inhaler) in a 
carrier gas (Ari et al., 2009). Aerosol delivered through the inhalation route has been used 
widely to treat different diseases such as COPD, asthma, cystic fibrosis, and pneumonia. 
It has advantages over the systematic route, such as the ability to use smaller doses, a 
faster onset of the effects, the topical application of a drug to the lungs, and less 
systematic side effects. In addition, aerosol therapy is painless, and it often results in 
better clinical outcomes when compared with a much larger oral dose or even with a 
subcutaneous injection of the drug (Ari et al., 2009). Aerosolized medications include but 
are not limited to: long- and short-acting adrenergic bronchodilators, long- and short-
acting anticholinergic bronchodilators, inhaled corticosteroid, xanthines, mucus-
controlling drugs, surfactant agents, mast cell stabilizing agents, antileukotriene agents, 
and anti-infective agents (Gardenhire, 2007). Short-acting beta agonists such as albuterol 
are the most common inhaled medication that is being used for NIPPV and aerosol 
research, and it is administered either by a pMDI or by a small volume nebulizer (SVN) 
(Branconnier & Hess, 2005; Mukhopadhyay, Dela Pena, Wadden, Procyshyn, & Keang 
Lim, 2009; Nava, Karakurt, Rampulla, Braschi, & Fanfulla, 2001). 
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Patients receiving NIPPV may require aerosol therapy for several reasons because 
NIPPV and aerosol are two modalities that are administered for similar diseases and 
conditions. COPD and asthma, for example, are two common pulmonary diseases with 
airflow limitation and may benefit from aerosol therapy, NIPPV, or both. Combining 
both modalities could result in better deposition and consequently better clinical 
improvement (Brandao et al., 2009; Nava et al., 2001; Pollack, Fleisch, & Dowsey, 1995) 
or at least fewer complications from discontinuation of mechanical support. In addition, 
providing this combination could save therapist time, effort, and cost. Unfortunately, 
there is a lack of in vivo and in vitro research regarding use of aerosol therapy in patients 
receiving NIPPV.  
Significance of The Study 
More research is needed to understand the efficacy of aerosol therapy in 
conjunction with NIPPV. To improve aerosol delivery during NIPPV, the physical and 
physiological aspects of this type of therapy during NIPPV need to be studied. 
Additionally, research thus far has not definitively determined which device should be 
used to optimize aerosol deposition. Clearly, more studies are needed to establish which 
mask achieves the highest possible aerosol deposition. In addition, no published study has 
compared the JN, the pMDI, and the VMN.  Also, there no study in the literature 
evaluating the efficiency of the HFA format of pMDI during NIPPV. The efficiency of 
different masks used during NIPPV is also unknown. No study thus far has looked at the 
efficiency of the new VMN (NIVO) that is designed specifically for NIPPV. 
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Purpose of The Study 
The purpose of this study was first to determine the efficiency of a JN versus a 
vibrating mesh nebulizer versus a pressurized metered-dose inhaler, and second to 
compare the efficiency of the Performax mask, the AF531 oro-nasal mask, and the 
Performa track mask during NIPPV using two different VMNs. 
 
Research Questions of The Study 
The research questions for this study include the following: 
1) What is the efficiency of JN, VMN, and pMDI during NIPPV? 
2) What is the difference in aerosol deposition among three different masks during 
NIPPV? 
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CHAPTER II  
REVIEW OF LITERATURE 
This literature review examines articles published in the area of aerosol delivery 
during NIPPV. The search terms used to gather studies for this review included the 
following: nebulizer, pMDI, SVN, mesh, bronchodilator, nebulization, inhalation 
therapy, metered-dose inhaler, small volume nebulizer, inhalers, aerosol therapy, 
noninvasive positive pressure ventilation, mask ventilation, positive pressure respiration, 
continuous positive airway pressure, positive airway pressure, bilevel positive airway 
pressure, and noninvasive ventilation. These search terms were utilized together to find 
articles in different databases such as Cochrane Reviews, Sciencedirect, Web of Science, 
the Cumulative Index to Nursing and Allied Health Literature, and MEDLINE (pubmed). 
Relevant articles are presented in the following five sections: (1) bench model studies, (2) 
clinical studies, (3) studies that include both a bench model and a clinical aspect, (4) 
NIPPV, and (5) aerosol generators. In vitro studies are included in the bench model 
section only, and in vivo studies are included only in the clinical section. If the same 
study includes both in vivo and in vitro components, it is presented in the section entitled 
―studies including in-vitro and in-vivo components.‖  
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Bench Studies 
 Chatmongkolchart, Schettino, Dillman, Kacmarek, and Hess’s (2002) in vitro 
study evaluated the effects of ventilator settings and nebulizer position on aerosol 
bronchodilator delivery during NIPPV. Their model consisted of 1) a double-chamber 
lung model, 2) a mechanical ventilator, 3) a bilevel positive airway pressure (BiPAP) 
machine (Respironics, Murrysville, PA), and 4) a small volume nebulizer (SVN) 
(Micromist, Hudson RCI, Temecula, CA), which was connected either proximally or 
distally to the BiPAP. Albuterol delivery with BiPAP was evaluated at a respiratory rate 
of 10 BPM and 20 BPM at inspiratory positive airway pressures and expiratory positive 
airway pressures (IPAP/EPAP) of 10/5, 15/5, 20/5, 15/10, 20/10, and 25/10 cm H2O, 
respectively. The albuterol delivery from the SVN with the BiPAP ventilator ranged from 
5.2 ± 0.4 to 24.5 ±1.3% of the nominal albuterol dose. They reported that albuterol 
delivery was significantly affected by the BiPAP settings, the nebulizer position, and the 
respiratory rate. They detected the greatest albuterol delivery when the nebulizer was 
connected at the distal position with a respiratory rate of 20 BPM. Under these 
conditions, as the inspiratory pressure levels increased, so did the albuterol delivery. In 
addition, increasing expiratory pressure levels decreased albuterol delivery.   
 Branconnier and Hess (2005) evaluated the effect of two aerosol delivery devices 
and the leak port position on albuterol delivery during NIPPV. The authors used a SVN 
(Micromist, Hudson RCI, Temecula, CA) and a BiPAP machine (BiPAP S/T30, 
Respironics, Murrysville, PA). They reported that the location of the leak port, the type of 
aerosol delivery device, and the timing of actuation of the pMDI have an impact on 
albuterol delivery with NIPPV. They reported three main findings from this study. First, 
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higher aerosolized bronchodilator delivery was detected when the leak port was in the 
circuit rather than the mask. Second, the aerosolized bronchodilator delivery using the 
pMDI with a spacer and the nebulizer was similar when the leak port was in the circuit, 
but when the leak port was in the mask, delivery was greater with the pMDI. Finally, the 
researchers detected a significant reduction in aerosolized bronchodilator delivery when 
the pMDI was actuated during the expiratory phase. Aerosol deposition percentage with 
both aerosol devices was about 9% when using a spectrum mask (Respironics, 
Murrysville, PA). When the pMDI was used with a mirage mask (resMed, Poway, CA) it 
was also 9%; however, it dropped to approximately 4% when an SVN was used with the 
mirage mask.  
 Calvert et al. (2006) investigated the differences in inhaled salbutamol during 
NIPPV at three different aerosol location compared with during spontaneous breathing( 
without circuit). The authors utilized a Pari COMPAS breath simulator (Pari GmbH, 
Starnberg, Germany) to model a patient with a sinusoidal breathing pattern. A bilevel 
ventilator (Knightstar 335, Mallincroft, UK) was connected to the breath simulator via a 
187-cm length NIPPV corrugated circuit. The bilevel ventilator was set on spontaneous 
mode with an IPAP/EPAP of 20/5. Five mg of salbutamol with 2.5 mL normal saline was 
nebulized for 5 minutes by a JN (Cirrus, Intersurgical Ltd., Wokingham, UK)  before the 
expiration port (position A) , after the expiration port (position B) or pre-ventilator ( 
position C). The authors concluded that IM was the highest at position B (647±76 µg) 
which was slightly more than position B (544±85µg). IM at position C was (267±26µg) 
which was less than IM (424±61 µg) during spontaneous.  Significance can be seen only 
between position B and C and between B and spontaneous.  
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 Abdelrahim, Plant, and Chrystyn (2010) conducted an in vitro study to detect the 
differences in IM when delivered during NIPPV at two different positions and via two 
different nebulizers. The authors contrasted an Aeroneb Professional (Aerogen Inc., 
Ireland) and a sidestream JN. The positions were either before expiratory port (position 
A) or after expiratory port (position B). The researchers utilized a breathing simulator 
machine (Compass; Pari GmbH, Germany) that was connected to a bilevel ventilator 
(Nippy2; B&D Electromedical, UK) via a 180-cm length of corrugated circuit with a 
fixed leak port. They found that the deposition was highest with the Aeroneb at position 
A (2572.2 ±150.9 µg) and second highest with the sidestream at position A (1204.2 
±1613µg). 
 
Clinical Studies 
Pollack et al. (1995) conducted a randomized prospective clinical study on 100 
afebrile, wheezing patients between the ages of 18 and 40 to find out whether beta-
adrenergic agonist aerosol is more effective in improving acute bronchospasm if 
delivered by nasal BiPAP (BiPAP S/T ventilator, Respironics) with an in-line SVN than 
by an SVN alone. The patients were randomly assigned to receive two doses of 
aerosolized albuterol via either an SVN alone or an SVN during BiPAP (either nose mask 
or face mask). In the SVN BiPAP group, aerosol was delivered through the circuit of the 
BiPAP with an IPAP of 10 cm H2O and an EPAP of 5 cm H2O. Arterial blood oxygen 
saturation (SpO2), peak expiratory flow rate, heart rate, and respiratory rate were 
measured before and after each treatment. The researchers found no differences in any of 
the measures between the two groups except for the percentage of the predicted peak 
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expiratory flow rate, which was significantly higher in the SVN BiPAP group after each 
treatment (p=.0011) and from their baseline to their final treatment (p=.0013).  
Nava et al. (2001) conducted a randomized control study on 18 stable patients 
with COPD to evaluate the feasibility and efficacy of delivery of inhaled salbutamol 
solution via an SVN with  intermittent positive pressure breathing (IPPB) (PR II 
Respiratory Unit, Puritan Bennett), a pMDI with a spacer (Volumatic, Allen & Hanburys, 
Greenford, UK) in a spontaneous breathing situation, or a pMDI during NIPPV (Helia, 
Saime, Savigny Le Temple, France). Patients were randomly assigned to receive one of 
four possible modalities of treatment for four consecutive days: 1) placebo via a pMDI 
with a spacer; 2) 400 µg of salbutamol via a pMDI with a spacer during spontaneous 
breathing; 3) 400 µg of salbutamol via a spacer fitted into the inspiratory limb of the 
circuit, directly after the wye of the circuit, with use of a pMDI and NIPPV; 4) 5 mg of 
salbutamol with 5 ml of saline solution delivered by IPPB. The NIPPV settings were as 
follows: pressure support of 14.3±1.8 cm H2O, a tidal volume guarantee of 10 ml/kg, and 
inspiratory trigger of 0.5 cm H2O, which were delivered by a full face mask. The authors 
found that salbutamol delivery during NIPPV is feasible and effective, and showed 
significant bronchodilation, which was confirmed by the measurement of forced 
expiratory volume in the first second (FEV1) and forced vital capacity (FVC) compared 
with the placebo group; however, the delivery using pMDIs with a spacer resulted in the 
best bronchodilation effect.  
França et al. (2006) conducted a clinical study on 13 healthy subjects to evaluate 
pulmonary radioaerosol deposition by a JN during NIPPV (BiPAP synchrony 
Respironics, Inc.; Murrysville, PA) with an IPAP setting of 12 cm H2O and an EPAP 
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setting of 5 cm H2O compared with spontaneous breathing nebulization. The radioaerosol 
used with both groups was Tc99m-DTPA (25 mCI), which was nebulized by a JN (ST3; 
NS; Sao Paulo, Brazil). Immediately after nebulization, images were taken of the 
patients’ pulmonary fields using a scintigraphy camera. França et al. compared the 
pulmonary fields of each group. They reported that there was less radioaerosol deposition 
during NIPPV compared with spontaneous breathing nebulization (p<0.001), and they 
found a significant correlation between tidal volume and radioaerosol deposition.  
Reychler et al. (2007) conducted a clinical study on six healthy subjects to 
compare lung deposition of amikacin—measured indirectly by urinary excretion—
nebulized by a JN (sidestream; Medic-aid; West Sussex) with or without continuous 
positive airway pressure (CPAP) (Boussignac; Vygon; Belgium) at a pressure of 6 cm 
H2O. Patients underwent two nebulization sessions (one during CPAP and one 
spontaneous) in a random order with a one-week washout period between the sessions. 
After one day of nebulization, urine was collected at each spontaneous urination. The 
authors found that urine excretion of amikacin in the CPAP group was significantly lower 
(1.97% initial dose versus 4.88 initial dose, p<0.001) compared with those who received 
nebulization without CPAP.  
Brandao et al. (2009) conducted a randomized controlled study on 36 patients 
with severe asthma to compare the effect of jet nebulization (ST3; NS; Sao Paulo, Brazil) 
during spontaneous breathing with nebulization during NIPPV (BiPAP synchrony 
Respironics, Inc.; Murrysville, PA). The pressure settings for NIPPV were an IPAP of 15 
cm H2O and an EPAP of 5 cm H2O, or an IPAP of 15 cm H2O and an EPAP of 10 cm 
H2O. Respiratory rate, heart rate, SPO2, peak expiratory flow, FEV1, FVC, and forced 
11 
 
expiratory flow between 25 and 75% (FEF25%-75%) were measured before and 30 minutes 
after each treatment. The authors stated that nebulization during NIPPV resulted in 
significant improvement in peak expiratory flow, FVC, FEV1, and FEF25%-75% compared 
with jet nebulization alone. This improvement was better when the delta pressure was 
smaller and the EPAP was higher. The researchers suggested that this result could be 
explained by the higher possibility of laminar flow when delta pressure is smaller.  
Studies including in-vitro and in-vivo components 
Parkes and Bersten (1997) conducted in vitro study followed by a clinical study 
on nine stable asthmatic subjects to investigate the effects of CPAP on aerosol kinetics 
and bronchodilator efficacy. In their bench model, spontaneous breathing was simulated 
by using two compartments connected by a bar. The compartments simulated the 
respiratory muscle and the lung, which was attached to a circuit and a face mask, 
connected to a ventilator. The ventilator settings were either a fixed tidal volume of 500 
ml with a varied inspiratory flow, frequency, and minute volume or a fixed minute 
volume of 10 liter per minute (LPM) with a varied tidal volume. CPAP was set at a 
pressure of 10 cm H2O with a flow of 50 LPM. Technetium with 3 ml of saline was 
nebulized with a flow rate of 6 LPM and connected proximally to the mask and the CPAP 
machine. In this clinical study all subjects underwent nebulization during CPAP and 
nebulization only. Salbutamol was given at incremental doses of 250 µg, 250 µg, 500 µg, 
and 1000 µg at 30-minute intervals. For the nebulizer (Bird Micronebuliser, Bird, CA) 
group, the same doses were given but without the CPAP. FEV1 was measured after 5 and 
30 minutes of nebulization. The researchers found that CPAP resulted in a lower IM%, 
from 6.85± 1.52 % in the control group to 1.3±0.37% in the CPAP group. In the clinical 
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study, CPAP did not result in a significant change in the bronchodilation response 
measured by FEV1 when compared to the control group.  
 Smedsaas-Löfvenberg, Nilsson, Moa, and Axelsson (1999) conducted an in vitro 
study followed by a clinical study on five infants to develop and evaluate a safe method 
to provide nebulization during CPAP. The bench model was conducted by modifying a 
nasal CPAP system (Infant Flow ™; EME, Brighton, UK) to add the ability to deliver 
nebulization (Aiolos AB, Karlstad, Sweden). The particle size was measured using a 
Malvern Laser 2600 at a pressure of 2.0-3.0 bars (corresponding to a gas flow of 8.0–
10.15 LPM-1). The mass median aerosol diameter (MMAD) of the surfactant was 0.7–
0.9 µm, which is very similar to the MMAD for ribavirin generated by the Small Particle 
Aerosol Generator Model-2. The same model was used to deliver ribavirin to treat five 
infants with a respiratory syncytial virus infection. All patients made a complete recovery 
with minimal complications. 
 Fauroux et al. (2000) conducted in vitro and in vivo studies to evaluate the 
efficacy of NIPPV (Onyx; Mallinckrodt, Les Ulis, France) in optimizing IM. In the in 
vitro study, the researchers compared the performance of two actuated nebulizers, of 
which one was patient-triggered (Optined; Air Liquid Santé, Paris, France) and the other 
was positive pressure–triggered (Optiplus; Air Liquid Santé). They reported that the 
MMAD for both nebulizers was very similar (3.21±0.13 and 3.16 ± 0.02, respectively). 
In the in vivo study, 18 clinically stable cystic fibrosis patients underwent one control 
session (nebulization alone) and one session of nebulization during NIPPV. Aerosol 
deposition, which was estimated by radioactive imaging, was significantly higher in the 
nebulization-during-NIPPV sessions (15.3 ± 8.3 compared with 11.5 ± 5.7, respectively). 
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The researchers concluded that adding NIPPV to nebulization could enhance total IM 
without impacting the regional deposition.  
Noninvasive Positive Pressure Ventilation  
  Criner, Travaline, Brennan, and  Kreimer (1994) conducted a clinical study on 
nine patients with chronic respiratory failure to evaluate the efficacy of using a full face 
mask during NIPPV. The researchers utilized three different types of masks: 1) a full face 
mask (Total, Respironics, Monroeville, PA), 2) a nasal CPAP mask (Respironics), and 3) 
a nasal/oral mask (Vitalog, Vital Signs). Patients were assigned to receive NIPPV for 20 
to 30 minutes via different masks in a random order. In addition, multiple tests were 
performed on patients before initiating NIPPV and after each session of NIPPV. All 
masks resulted in a significant improvement in gas exchange, with the best results 
attained using the full face mask. However, dyspnea, discomfort, and leakage were 
significant (p<0.05) when the full face mask was used.  
Plant, Own, and Elliott (2001) conducted a prospective, multicenter, randomized, 
controlled study on 236 patients with acute exacerbation of COPD. The researchers had 
two aims. First, they hoped to determine the variables that could be used to divide 
patients according to their risk of needing invasive mechanical ventilation. The second 
aim was to ascertain long-term mortality rates associated with using or not using NIPPV. 
Patients were randomized to receive either NIPPV or a standard treatment. Arterial blood 
gases and respiratory rate were recorded at admission, after one hour, and after four 
hours. In the standard treatment group, 27% of the patients required intubation compared 
to only 15.3% of the NIPPV group (p<0.02). The in-hospital mortality rate was 20% for 
the standard group and 10% for the NIPPV group. The authors recommended the use of 
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NIPPV as a first line of intervention in addition to standard medical care to manage acute 
exacerbation of COPD. 
Miyoshi, Fujino, Uchiyama, Mashimo, and Nishimura (2005) studied the effects 
of the gas leak that commonly occurs during NIPPV on triggering function, 
humidification, and fraction of inspired oxygen (FiO2) in bilevel pressure ventilators and 
ICU ventilators. The authors evaluated two ICU ventilators (Puritan Bennett 7200ae and 
Puritan Bennett 840; Tyco Healthcare; Mansfield, MA) and two bilevel pressure 
ventilators (BiPAP S/T-D and BiPAP vision; Respironics; Murrysville, PA). The 
researchers set the machines to an IPAP of 15, an EPAP of 5 cm H2O, and an FIO2 of 
0.21. A leak was created in the airway opening of the lung model with several holes sizes 
to allow gas to leak from 1.1 to 44.2 LPM. They reported that bilevel pressure ventilators 
were able to compensate for all leak sizes adequately, whereas ICU ventilators were not 
able to do so with large leaks, which resulted in uncontrolled triggering. The authors were 
able to predict the FiO2 when the leak was small but were unable to predict it when the 
leak was large (>15 LPM). Gas leaks caused minimal changes in humidification.  
Moerer et al. (2006) conducted an in vitro study to evaluate two types of interface 
for NIPPV, comparing them with invasive ventilation. The following interfaces were 
used by the authors: 1) a helmet (Starmed Castar R; Mirandola; Modena, Italy) and 2) a 
face mask (King Systems Corporation; Noblesville, IN). For the invasive ventilation, the 
model was connected to an endotracheal tube (Portex, 7.5 mm; Portex, Ltd.; Kent, UK). 
All systems were evaluated in terms of delay times, pressure time products, and wasted 
effort during inspiration, defined as the failure of the ventilator-driven chamber to 
activate the passively driven lung chamber. They reported that delay time was 
15 
 
significantly longer (p<0.001) when the helmet was used (144 to 174 ms) compared to 
invasive ventilation (66 to 76 ms) or the use of the face mask (70 to 74 ms); however, 
there were no significant differences in mean pressure time products among all the 
systems. The frequency of wasted efforts (failure of the ventilator-driven chamber to 
activate the passively driven lung chamber) increased with higher pressure support, 
higher respiratory rate, lower sensitivity, higher compliance, and the helmet interface.  
Conti et al.’s (2007) clinical study compared the efficacy of NIPPV delivered by 
helmet (CaStar, Starmed, Mirandola, Italy) versus face mask (Vital Signs, Totowa, NJ, or 
Dar-Tyco, Mirandola, Italy) in 50 patients with acute respiratory failure after abdominal 
surgery. The control group of 25 patients was selected from a historical group based on 
numerous factors to match with the intervention group. The matching was based on age, 
simplified acute physiology score II, and the ratio of arterial oxygen partial pressure to 
the fraction of inspired oxygen (PaO2/FiO2). The ventilator (300, Siemens, Uppsala, 
Sweden) was started at IPAP of 10 cm H2O with an incremental increase to achieve 
patient comfort of less than 25 BPM. EPAP was increased up to 12 cm H2O in order to 
maintain SpO2 over 90% with the minimal FiO2 possible. The authors reported that mask 
intolerance, major leaks, or ventilator-associated pneumonia were significantly higher in 
the face mask group (p<0.03). 
Roy, Cordova, Travaline, D’Alonzo, and Criner (2007) conducted a clinical study 
on 10 nonambulatory patients with acute respiratory failure to determine the effectiveness 
of a total face mask in the application of NIPPV. None of the patients were able to 
tolerate NIPPV via nasal mask (Respironics, Inc., Monroeville, PA) or oro-nasal mask 
(Respironics, Inc., Monroeville, PA); however, eight out of the 10 patients were managed 
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successfully when NIPPV was delivered via a total face mask (Respironics, Inc., 
Monroeville, PA), and the other two required endotracheal intubation due to excessive 
secretions. Patients were ventilated by NIPPV (BiPAP, Respironics, Inc., Monroeville, 
PA) with an initial IPAP of 21 cm H2O and EPAP of 3 cm H2O with an average delta 
pressure of 18±4 cm H2O. The authors suggested using a total face mask with patients 
who could not tolerate NIPPV with a nasal or oro-nasal mask. 
Aerosol Generators 
 Deerojanawong et al. (2005) conducted a double-blind, randomized controlled 
trial on 47 young children with wheezing to compare the efficacy of salbutamol aerosol 
therapy delivered by either a pMDI or a JN. Each patient was given either a placebo 
pMDI followed by a jet nebulization treatment or a placebo jet nebulization followed by a 
pMDI. Clinical outcomes were quantified by measuring each patient’s heart rate, 
respiratory rate, clinical scores, SpO2, and pulmonary function before and 30 minutes 
after each treatment. The authors concluded that there was no statistical difference 
between the groups in terms of clinical outcomes; however, heart rate was significantly 
higher in the jet nebulization group when compared with the pMDI group.  
 Pitance et al. (2010) conducted both in vitro and in vivo studies to compare the 
IM and urinary drug concentration of amikacin in three aerosol delivery systems: a 
standard JN (sidestream, Philips-Respironics, Pittsburgh, PA) with and without a 110-ml 
corrugated piece of tubing and a VMN (e-Flow Rapid, PARI, Pharma GmbH, Munich, 
Germany). All systems were assessed for particle size distribution using a Malvern 
Mastersizer-X laser particle sizer (Malvern Instruments Ltd., Worcestershire, UK) during 
the in vitro study; however, during the in vivo study the IM was measured indirectly by 
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the urinary excretion of amikacin. The authors reported that during the in vitro portion of 
the study, the IM% of the nominal dose was approximately 40% for the mesh nebulizer, 
25% for the JN with the corrugated tube, and 15% for the JN alone; however, there was 
no significant difference in MMAD among all three systems. The daily percentage of 
amikacin from the initial dose was 11.6% with the mesh nebulizer, 8.2% with the JN with 
the corrugated tube, and 6.15% with the JN alone. Both results suggest that the mesh 
nebulizer was able to deliver the highest amount of aerosol mass among the three 
systems. 
 Skaria and Smaldone (2010) conducted an in vitro study comparing IM, residual 
activity, MMAD, and run time (which is the time required to provide the nebulization by 
the system) with a radiolabeled albuterol for four aerosol systems. The systems compared 
in this study included a sidestream JN (Philips/Respironics, Parsippany, NJ), a breath-
enhanced nebulizer (Pari LC Plus, Pari Respiratory Equipment, Midlothian, VA), and a 
mesh nebulizer (Omron Healthcare, Inc., Bannockburn, IL), which was tested in both the 
tilted and the horizontal positions. All systems were ventilated with a Harvard pump and 
set to simulate a COPD patient with a tidal volume of 450 ml, a respiratory rate of 15 
BPM, and a duty cycle of 0.35. Particle distribution was quantified by using low flow 
cascade impaction. The authors found that the IM by the Omron and Pari were 
comparable (20% of the nominal dose) and higher than the sidestream (10%). However, 
MMADs were comparable for all systems (1.3–2.4)µm, but variability (1.9–3.5) µm was 
higher for the Omron in the horizontal position. Residual activates for the Omron in the 
tilted position were 25% CI (22–32) and 22% CI (18–25) in the horizontal position. 
Residual activates for the Pari LC were 57% CI(55-60) and 47% CI(45-49) for the 
18 
 
sidestream. The run time was significantly lower for the Omron in both positions 
compared with the JNs; however, it was about three times greater in the tilted position. 
 In an in vitro study, Ari, Areabi, and Fink (2010) compared the performance of 
four aerosol generators at three different locations in humidified and nonhumidified 
circuits during adult mechanical ventilation. They examined four aerosol generators—a 
JN, a VMN, an ultrasonic nebulizer, and a pMDI with a spacer—at three different 
locations: 1) between the endotracheal tube and the Y-piece, 2) 15 cm from the Y-piece, 
and 3) 15 cm from the ventilator. The ventilator settings were a tidal volume of 500 ml, a 
ramp flow pattern, 15 BPM, a peak inspiratory flow of 60 LPM, and a positive end 
expiratory pressure of 5 cm H2O. The drug deposition was collected by an absolute filter 
distal to an 8.0-mm endotracheal tube and was measured by spectrophotometry (276 
mm). The VMN was able to deliver 30.2% ±1.0, which was the highest IM% throughout 
the study, at location 2 with a nonhumidified circuit; in contrast, the pMDI delivered the 
least IM% 2.5% ± 0.8 at location 3 with a heated circuit. The authors reported that the 
humidified circuit had the overall effect of decreasing IM in all positions and with all 
generators. 
 Ari, Atalay, et al. (2010) conducted an in vitro study to determine the impact of 
nebulizer type, position on the ventilator circuit, and bias flow on aerosol delivery in 
simulated and mechanically ventilated pediatric and adult lung models. The study used a 
JN and a VMN. The JN was set at 15 cm proximal to the wye (position 1) or 15 cm prior 
to the heated humidifier (position 2). The VMN was attached directly to the wye, at the 
inlet of the humidifier. Bias flow was either 2 liters per minute (LPM) or 5 LPM. The 
highest IM% , 23.8% ±1.0, was attained with the adult lung model at position 2 with a 2 
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LPM bias flow, delivered by VMN; in contrast, the lowest IM%, 3.8 %± 0.3, was 
measured using the pediatric lung model at position 1 with a 5 LPM bias flow delivered 
by JN. In all conditions, the IM was two- to four folds greater when using the VMN.  
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CHAPTER III  
METHODOLOGY 
Lung Model 
This model consists of a BiPAP ventilator (BiPAP S/T30, Respironics, 
Murrysville, PA) and a single-limb NIPPV circuit (Philips, Respironics, PA). In this in-
vitro model, a breathing adult was simulated. The BiPAP machine was set on the 
spontaneous/time mode with a respiratory rate of 15 BPM and an inspiratory time of 1.0 
second, with pressures settings of IPAP/ EPAP 20/5 cm H2O. The single-limb NIPPV 
circuit was connected between the BiPAP machine and the mask, which was tightly 
strapped to the head of the manikin. Each aerosol generator that was used in this study 
was attached between the mask and the single-limb circuit.  
First Experiment 
Aerosol Generators Type, Dose, Location, and Operation  
Three different aerosol generators were investigated in this study: 1) a JN (Micro 
Mist, Hudson RCI, Temecula, CA), 2) a pMDI (ProAir HFA, Teva Specialty 
Pharmaceuticals, Atlanta, GA) with a spacer, and 3) a VMN (Aeroneb Solo, Aerogen, 
Mountain View, CA). All generators were placed between the AF531 oro-nasal mask 
(Respironics, Inc., Murrysville, PA) and the circuit. The JN was pressurized with 8 LPM 
O2 and a 2.5 mg/3 ml unit dose of albuterol (Nephron Pharmaceuticals, Orlando, FL) and 
connected at the vertical position (Figure 1). Nebulization continued until sputter. The 
pMDI was shaken and primed, then connected at the same location (Figure 2). The pMDI 
actuation synchronized at the beginning of the inspiratory cycle for a total of four 
actuations, separated by at least 15 seconds. The pMDI was connected to a spacer either 
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at the normal position (recommended by the company) which was abbreviated as pMDI-
N or the reversed position (pMDI-R). The VMN was connected at the same location, and 
a 2.5 mg/3 ml unit dose was placed into the nebulizer (Figure 3). The nebulizer was run 
continuously until sputter. 
 
 
Figure 1. Lung model with the jet nebulizer. 
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Figure 2. Lung model with the pMDI. 
 
Figure 3. Lung model with the vibrating mesh nebulizer. 
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Second Experiment 
Masks Types  
 The same lung model was reassembled for the second experiment. Two 
different VMNs were used: an Aeroneb Solo (Aerogen, Mountain View, CA) and a 
NIVO (Phillips Respironics, Ireland). Three masks were used: 1) a Performax mask 
(Respironics, Inc., Murrysville, PA), 2) an AF531 oro-nasal mask (Respironics, Inc., 
Murrysville, PA), and 3) a Performa track mask (Respironics, Inc., Murrysville, PA). The 
Performax mask was investigated with both mesh nebulizers (Aeroneb Solo and NIVO). 
The Performa track mask was only tested with the Aeroneb Solo due to the inability to 
connect with the NIVO. 
 
 
 
 
 
 
Measurement of Aerosol deposition 
An absolute filter (Respirgard II, 303, Vital Signs, Totowa, NY) was attached and 
placed at the wye connection, where two simulated bronchi from the manikin meet. After 
each test was completed, the filter was shaken for at least one minute after being washed 
with 0.1 molar N HCl. The concentration of albuterol from the filter was measured via a 
spectrophotometer (Beckman Instruments, Fullerton, CA). 
Figure 4. From left to right, Performax mask, AF531 oro-nasal mask, Performa track mask 
24 
 
Data Analysis 
Albuterol deposition was quantified and reported as a percentage of the nominal 
dose. Data analysis and graphs were created using Statistical Package for the Social 
Sciences (IBM SPSS, 18.0, Armonk, NY) and Microsoft office Excel (2007,Redmond, 
WA).  Means and standard deviations were calculated for the three generators. A one-
way ANOVA test was used not only to compare the means of albuterol deposition of the 
three generators on the first experiment, but also to compare means of albuterol 
depositions and residual volume among the three different masks on the second 
experiment. An independent t-test was used to compare residual volume in the VMN and 
the JN on the first experiment and to compare the Aeroneb Solo and the NIVO in the 
second experiment. A significance level of 0.05 was used for all comparisons.  
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CHAPTER IV 
 RESULTS 
In the first experiment, descriptive statistics were computed for IM, IM%, and 
residual volume (Table 1). In addition, inferential statistics were used to compare the 
means and to identify the significance levels IM, IM%, and residual volume. The 
ANOVA comparing the means of IM during NIPPV varied significantly (p<0.05): the JN 
and the VMN resulted in a significance level of p=0.005; the JN and the pMDI in the 
reversed position (pMDI-R) had a significance level of p=0.002; the JN and the pMDI in 
the normal position (pMDI-N) was significant at the p=0.001 level; the VMN and the 
pMDI-R resulted in a significance level of p=0.002; and the VMN and the pMDI  (in 
both positions) had a significance level of p=0.002. The difference between the pMDI-N 
and the pMDI-R was not significant (p=0.253). Of the delivery devices tested, the VMN 
produced the highest IM (0.72 mg ± 0.48 mg) with the highest IM% (28.83% ± 1.93%). 
In addition, the VMN had a significantly lower residual volume than the JN (p=.000). 
The mean residual volume of the VMN was 0.10 ml ± 0.069, whereas the mean residual 
volume of the JN was ml 1.65 ±.14. 
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Table 1 
Means and SDs of inhaled mass, inhaled mass percent and residual volume of each 
aerosol device used in this study. JN: jet nebulizer VMN: vibrating mesh nebulizer, 
pMDI-N= pMDI normal position, pMDI-R: pMDI retrograde position 
 JN VMN pMDI-N pMDI-R 
Inhaled Mass (mg) 0.33 ± 0.02 0.72 ± 0.05 0.10 ± 0.01 0.09 ± 0.01 
Inhaled Mass Percent (%) 13.12 ± 0.72 28.83 ± 1.93 23.53 ± 2.03 21.38 ± 0.32 
Residual volume (g) 1.65 ± 0.14 0.10 ± 0.07   
 
 
Figure 5. Inhaled mass percentage differences between devices.  
* p<0.05 
 
* 
* 
* 
* 
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Figure 6. Residual volume between JN and VMN.  
* p<0.05 
In the second experiment, results indicate that aerosol delivery during NIPPV 
with the three different masks and the two different VMNs varied significantly (p<0.05).  
However, the only statistically significant relations are between the oro-nasal mask–
Aeroneb Solo VMN setup and each of the other setups. For example, the oro-nasal mask–
Aeroneb Solo setup compared with the Performax mask–Aeoneb Solo was significant at 
the p= 0.003 level. This same setup had the following results when compared with other 
combinations: the oro-nasal mask–NIVO VMN (p=0.023), the Performax mask–NIVO 
VMN (p=0.001), and the Performa track mask–Aeroneb Solo VMN (p= .000). All other 
relations were not significant.  
In conclusion, the findings of this study showed that VMN was the most efficient 
aerosol generator with the lowest residual volume. However, pMDI could be an attractive 
alternative to VMN since it provide a close IM%. Oro-nasal mask with Aeroneb solo 
* 
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provided the highest aerosol deposition and may be consider as a first option for aerosol 
therapy during NIPPV. Other masks did not differ statistically. Therefore, the mask 
selection should be based on patient’s need and comfort level, and mask availability..  
 
Table 2 
Inhaled Mass and Inhaled Mass Percent Among the Five VMN–Mask Combinations 
 Performax 
mask–NIVO 
VMN 
Performax 
mask–
Aeroneb Solo 
VMN 
Oro-nasal 
mask–
NIVO VMN 
Oro-nasal 
mask–
Aeroneb Solo 
VMN 
Performa 
track mask–
Solo VMN 
Inhaled mass 0.49 ± 0.026 0.53±0.048 0.58±0.018 0.72±.048 0.46±0.062 
Inhaled mass % 20 ± 1.05 21±1.93 23±.70 29±1.92 19±2.46 
 
 
Figure 7. Inhaled mass percentage differences among different masks. * p<0.05 
* 
* 
* 
* 
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CHAPTER V 
DISCUSSION 
The findings of this study demonstrate the efficiency of aerosol devices and 
masks used during NIPPV. The VMN provided the highest IM and IM% to the filter 
(0.72 mg ± 0.05 mg, 28.83 % ± 1.93%, respectively). In comparison, the JN provided the 
second-highest IM with the lowest IM% (0.33 mg ± 0.02 mg, 13.12% ± 0.72%, 
respectively). The pMDI, in both orientations, delivered the lowest IM with the second-
highest IM%. The VMN was more efficient than the JN by providing significantly lower 
residual volumes (0.10 ± 0.07 mL). In the second experiment, the oro-nasal mask with 
the Aeroneb Solo VMN provided the highest IM with the highest IM% (0.72 ± 0.05, 
28.83% ± 1.93%, respectively). This mask resulted in a significant difference when 
compared with any other mask or setup used in this study.  
 This study used NIPPV machine that is commonly used in acute and chronic 
conditions with ventilator settings that have been used in four published in vitro aerosol 
studies focused on using NIPPV (Abdelrahim et al., 2010; Branconnier & Hess, 2005; 
Calvert et al., 2006; Chatmongkolchart et al., 2002). When different aerosol devices and 
masks were utilized during NIPPV in an adult lung model, the IM varied between 0.09 
mg and 0.72 mg, representing 13% to 29% of the emitted or nominal dose. The second 
experiment found the highest IM when the oro-nasal mask was used with the Aeroneb 
Solo VMN (0.72 mg ± 0.05 mg), which was approximately two-fold higher than with the 
JN and seven-fold higher than with the pMDI at either position. These findings are 
consistent with those of Ari, Areabi, and Fink (2010) when comparing VMN, pMDI and 
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JN. Two other studies, however, reported considerably higher IM. Using a VMN, 
Abdelrahim et al. (2010) reported an IM of 2572.5 µg ±150.9 µg. using a JN, Calvert et 
al. (2006) found an IM of 647 µg ±67 µg. The adult lung model is the key to 
understanding the difference in results between these studies and the present study. 
Abdelrahim et al. and Calvert et al. both used a model in which they attached the 
inhalation filter directly to the circuit; in this study, the inhalation filter was attached to 
the wye connection, distal to the two simulated main bronchi. In addition, both of the 
other studies used a higher nominal dose than in the present model, which clearly could 
have increased  aerosol deposition. Additionally, Abdelrahim et al. used a different 
medication (terbutaline 5.0 mg), which could has different chemical and physical 
proprieties than albuterol. Theoretically, our study model provides a more realistic 
estimation of the human lung configuration with inhaled medications. 
 Branconnier and Hess (2005) utilized a more realistic model with an actual non-
invasive mask when compared with other studies. Their findings demonstrate a better 
aerosol deposition with the spectrum mask (which had a leak port at the circuit) when 
compared with the mirage mask (leak port at the mask); however, their IM with Spectrum 
mask (450 µg for the JN and 50 µg for the pMDI) was not similar to ours. This difference 
might be explained by their use of an invasive ventilator (model 840 Puritan-Bennett, 
Carlsbad, CA). Non-invasive ventilators support leak control, but invasive ventilators—
like the one used by Branconnier and Hess—may not. This could lead to less bias flow in 
the circuit, which has been shown to have an impact on aerosol delivery (Ari, Atalay, et 
al., 2010). In addition, the Branconnier and Hess’s study was published before the 
introduction of pMDI with hydrofluoroalkane (HFA), which is well-known to promote 
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better aerosol delivery when compared with chlorofluorocarbon. Indeed, they used higher 
nominal dose (5.0 mg compared to 2.5 mg) and lower IPAP (15 cm H2O compared to 20 
cm H2O). Interestingly, Chatmongkolchart et al. (2002) reported about 25% IM% 
compared to approximately 13% in our study with the same JN (Micromist); however, 
they used a larger albuterol dose (5.0 mg compared to 2.5 mg) with a higher respiratory 
rate (20 BPM compared to 15 BPM). Both factors can lead to higher aerosol deposition . 
In addition, they did not utilize a noninvasive mask in their model, and the filter was 
connected directly to the circuit. 
 Our study used S/T mode with IPAP/EPAP of 20/5 cm H2O and RR 20 BPM with 
no spontaneous effort. Those fixed settings may not mimic the clinical dynamic situation 
for patient with airway limitation.  
 For further studies, we suggest studying the effect of humidification on IM during 
NIPPV.  Another suggestion is to study the effect of pMDI doses on aerosol delivery 
during NIPPV.  
In conclusion, the JN was less efficient than the VMN and the pMDI in either 
orientation. The type of aerosol device used during NIPPV influenced aerosol delivery in 
this simulated adult lung model. Oro nasal mask with Aeroneb Solo VMN provided the 
highest aerosol delivery. This was an in vitro study and thus results could differ when 
reproduced in an in vivo setting with considerable biological variability; however, our 
findings can serve as a guide for clinical research and can be used to support a clinical 
judgment.  
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